World Heart Day 2021 World Heart Day is a global health campaign. Its main task is to raise awareness about diseases of the cardiovascular system, the reasons for their occurrence and how to prevent them. For the first time, cardiologists at an international congress in 2012 announced the need to establish a holiday. Then, in the presence of world leaders, shocking numbers were announced. More than 18 million people die from cardiovascular diseases worldwide every year.
What's New in the AHA/ASA Secondary Stroke Prevention Guidelines? Clinical Context Risk for recurrent stroke or TIA is high but can be lowered by appropriate secondary stroke prevention. As secondary stroke prevention strategies have improved in recent years, cohort studies have shown decreased rates of recurrent stroke and transient ischemic attack (TIA).
Three or more eggs a week increase your risk of heart disease and early death, study says It's been debated for years: Are eggs good or bad for you? People who eat an added three or four eggs a week or 300 milligrams of dietary cholesterol per day, have a higher risk of both heart disease and early death compared with those who eat fewer eggs, new research finds.
e-Cigarettes Linked to Increased Stroke, MI Risk Use of electronic cigarettes (e-cigarettes) is linked to a significantly increased risk for "hard" adverse outcomes, such as stroke and myocardial infarction (MI), new research suggests. Among more than 400,000 respondents older than 18 years from the 2016 Behavioral Risk Factor Surveillance System (BRFSS) survey, almost 66,800 reported having ever used e-cigarettes.
INTERNATIONAL YOUNG ACADEMY OF CARDIOLOGY CONGRESS INTERNATIONAL YOUNG ACADEMY OF CARDIOLOGY CONGRESS
Personal income may increase risk of heart disease Income levels, if they are unstable, can easily turn into a stressor. However, the volatility of personal income could be having a more serious effect on people's heart health. It is often expected that a person's income will constantly rise until they reach retirement age.
Weight-Adjusted Aspirin Dosing: Evidence Builds in Primary Prevention Low-dose aspirin intended for primary prevention, typically 75 to 100 mg once daily, doesn"t protect against cardiovascular events in persons who weigh at least 70 kg (about 154 pounds), suggests a patient-level analysis of randomized trials that included more than 100,000 patients. But daily aspirin at higher dosages, usually at least 300 mg, was cardioprotective in that group, as was low-dose aspirin in people who weighed less than 70 kg.
New ADA/EASD Guidance on Diabetes: Assess CV Status First The treatment approach to type 2 diabetes should begin with an assessment of cardiovascular disease (CVD) status, other comorbidities, and patient preferences, according to a draft of the upcoming 2018 joint consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). The final version of the 2018 update to the current 2015 ADA/EASDManagement of Hyperglycemia in Type 2 Diabetes statement (Diabetes Care.2015;38:140-149) will be presented on October 5, 2018 at the EASD annual meeting in Berlin and will be published in Diabetes Care and Diabetologia.
Expert opinion. Double antiplatelet therapy after ACS: "de-escalation" In medical practice, cases in which patients with acute coronary syndrome (ACS) and received a combination of acetylsalicylic acid (ASA) with prasugrel or ticagrelor are often used, a combination of ASA with clopidogrel is started. This transition from more active platelet-derived P2Y12 blockers to less active clopidogrel has been termed "de-escalation." The possibility of "de-escalation" is considered in documents prepared by various expert groups. Among them, an updated version of the recommendations of the European Society of Cardiology and the European Association of Cardio Thoracic Surgeons for double antiplatelet therapy for coronary heart disease, where a similar transition is proposed to be discussed with side effects or intolerance of prasugrel / ticagrelor. There is also an agreement of experts from Europe and the USA, in which practical approaches to the replacement of the P2Y12 blocker of the platelet receptor are analyzed in detail. However, it should be borne in mind that these proposals are basically based on common sense and representations of the pharmacological properties of various P2Y12 receptor blockers of the platelet, while the evidence base for "de-escalation" is small.